Investing Ideas
/
Malaysian Pharmaceuticals & Biotech Strong Past Earnings Growth, P/E Ratio Below 20

Malaysian Pharmaceuticals & Biotech Strong Past Earnings Growth, P/E Ratio Below 20

Name: Financial Insights Based on S&P Global Market Intelligence
Creator: Simply Wall St Pty Ltd
License: https://www.spglobal.com/content/dam/spglobal/corporate/en/documents/secure/MI-FastTrack-Terms-and-Conditions-July-2023.pdf

Results

1 new

A list of companies that grew earnings by 20% and are trading on less than 20 times earnings. All with a debt to equity ratio below 1.

1 companies

Duopharma Biotech Berhad

Market Cap: RM 1.2b

An investment holding company, researches, develops, manufactures, distributes, and imports pharmaceutical products and medicines in Malaysia and internationally.

New

DPHARMA

RM 1.29

1.6%

4.9%